AMENDMENT OF THE CLAIMS

1-21. (Withdrawn)

22. (Original) A composition comprising a plurality of solid amorphous dispersion particles comprising a drug and a polymer wherein said particles have an average diameter of at least 40 μm and a bulk specific volume of less than 5 mL/g, and wherein at least 80 vol% of said particles have diameters of greater than 10 μm.

23. (Original) The composition of claim 22 wherein at least 90 vol% of said particles have diameters of greater than 10 μm.

24. (Original) The composition of claim 22 wherein said particles have an average diameter of at least 50 μm.

25. (Original) The composition of claim 22 wherein said particles have a bulk specific volume of less than 4 mL/g.

26. (New) The composition of claim 22 wherein said drug is selected from the group consisting of antihypertensives, antianxiety agents, anticlotting agents, anticonvulsants, blood glucose-lowering agents, decongestants, antihistamines, antitussives, antineoplastics, beta blockers, anti-inflammatories, antipsychotic agents, cognitive enhancers, anti-atherosclerotic agents, cholesterol-reducing agents, antiobesity agents, autoimmune disorder agents, anti-impotence agents, antibacterial and antifungal agents, hypnotic agents, anti-Parkinsonism agents, anti-Alzheimer's disease agents, antibiotics, anti-depressants, antiviral agents, glycogen phosphorylase inhibitors, and cholesteryl ester transfer protein inhibitors.

27. (New) The composition of claim 22 wherein said drug is selected from the group consisting of [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester; [2R,4S]-4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester; and [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester.

28. (New) The composition of claim 22 wherein said polymer is selected from the group consisting of ionizable cellulosic polymers, non-ionizable cellulosic polymers,

ionizable non-cellulosic polymers, non-ionizable non-cellulosic polymers, neutralized acidic polymers and blends thereof.

29. (New) The composition of claim 22 wherein said polymer is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxymethyl ethyl cellulose, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, polyvinyl alcohols that have at least a portion of their repeat units in hydrolyzed form, polyvinyl pyrrolidone, poloxamers, and blends thereof.

30. (New) The composition of claim 22 wherein said polymer is hydroxypropyl methyl cellulose acetate succinate.

31. (New) The composition of claim 30 wherein said drug is [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester and said polymer is hydroxypropyl methyl cellulose acetate succinate.

32. (New) The composition of claim 22 wherein said drug in said dispersion is substantially amorphous and said dispersion is substantially homogeneous.

33. (New) The composition of claim 22 wherein said polymer is a concentration-enhancing polymer.

34. (New) The composition of claim 33 wherein said concentration-enhancing polymer is present in an amount sufficient such that said solid amorphous dispersion, following administration to an *in vivo* or *in vitro* use environment, provides concentration enhancement of said drug in said use environment relative to a control composition consisting essentially of an equivalent amount of said drug alone.

35. (New) The composition of claim 34 wherein said composition provides a maximum drug concentration of said drug in said use environment that is at least about 1.25-fold that provided by said control composition.

36. (New) The composition of claim 34 wherein said composition provides in said use environment an area under the drug concentration versus time curve for any 90-minute period from the time of introduction to about 270 minutes following introduction

to said use environment that is at least 1.25-fold that provided by said control composition.

37. (New) The composition of claim 34 wherein said composition provides a relative bioavailability of said drug that is at least 1.25-fold that of said control composition.

38. (New) The composition of claim 22 wherein said solid amorphous dispersion particles are formed by a spray drying process, said process comprising the steps

(a) forming a feed solution comprising said drug, said polymer, and a solvent;

(b) directing said feed solution to a spray-drying apparatus;

(c) atomizing said feed solution into droplets in said spray-drying apparatus; and

(d) contacting said droplets with a drying gas to form said particles.

39. (New) The composition of claim 38 wherein said droplets have an average diameter of at least 50 μm and a D_{10} of at least 10 μm.

40. (New) The composition of claim 38 wherein said droplets have a D_{90} of less than about 300 μm.

41. (New) The composition of claim 38 wherein said droplets have a D_{90} of less than about 250 μm.

42. (New) The composition of claim 38 wherein said droplets have a Span of less than about 3.

43. (New) The composition of claim 38 wherein said droplets have a Span of less than about 2.